- Accession Number
- Small Molecule
Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Visipaque Injection, solution 270 mg/1mL Intravascular GE Healthcare Inc. 2002-12-13 Not applicable Visipaque Solution 652 mg Intra-arterial; Intravenous Ge Healthcare 1995-12-31 Not applicable Visipaque Solution 550 mg Intra-arterial; Intravenous Ge Healthcare 1995-12-31 Not applicable Visipaque Injection, solution 320 mg/1mL Intravascular GE Healthcare Inc. 2003-09-09 Not applicable
- International/Other Brands
- Visipaque 270 / Visipaque 320
- Acids, Carbocyclic
- Benzene Derivatives
- Compounds used in a research, industrial, or household setting
- Contrast Media
- Diagnostic Uses of Chemicals
- Drugs that are Mainly Renally Excreted
- Iodinated Contrast Agents
- Radiographic Contrast Agent
- Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media
- X-Ray Contrast Activity
- X-Ray Contrast Media, Iodinated
- CAS number
- Average: 1550.1819
- Chemical Formula
- InChI Key
- IUPAC Name
Iodixanol is a contrast agent during coronary angiography.
Iodixanol is a contrast agent commonly used during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. It is an iso-osmolar contrast agent, with an osmolality of 290 mOsm/kg H20, the same as blood.
- Mechanism of action
Organic iodine compounds attenuate x-rays as they pass through the body, thereby allowing the body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intravascular administration, iodixanol makes opaque those internal structures in its path of flow, allowing their visualization until significant hemodilution and elimination occur.
- Not Available
- Volume of distribution
- 0.26 L/kg
- Protein binding
- Route of elimination
In adults, approximately 97% of the injected dose of iodixanol is excreted unchanged in urine within 24 hours, with less than 2% excreted in feces within five days post-injection.
- Half life
2.1 hours. In patients with significantly impaired renal function (mean creatinine clearance rate, 9.91 [± 3.58] mL per minute), the plasma half-life is increased to 23 hours.
- Not Available
Non-ionic radiocontrast agents like iodixanol are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.
- Affected organisms
- Humans and other mammals
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
- Drug Interactions
Drug Interaction Abacavir Abacavir may decrease the excretion rate of Iodixanol which could result in a higher serum level. Acarbose Acarbose may decrease the excretion rate of Iodixanol which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Iodixanol which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Iodixanol which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Iodixanol which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Iodixanol which could result in a higher serum level. Aclidinium Iodixanol may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Iodixanol may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Iodixanol which could result in a higher serum level.
- Food Interactions
- Not Available
- Synthesis Reference
Ole Homestad, "Preparation of iodixanol." U.S. Patent US20020010368, issued January 24, 2002.US20020010368
- General References
- External Links
- ATC Codes
- V08AB09 — Iodixanol
- AHFS Codes
- 36:68.00 — Roentgenography
- FDA label
- Download (247 KB)
- Clinical Trials
- Not Available
- GE Healthcare Inc.
- Dosage forms
Form Route Strength Injection, solution Intravascular 270 mg/1mL Injection, solution Intravascular 320 mg/1mL Solution Intra-arterial; Intravenous 550 mg Solution Intra-arterial; Intravenous 652 mg
Unit description Cost Unit Visipaque 320 mg/ml cartridge 1.92USD ml Visipaque 270 mg/ml cartridge 1.57USD ml Visipaque 320 mg/ml vial 1.23USD ml Visipaque 270 mg/ml vial 1.13USD mlDrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent Number Pediatric Extension Approved Expires (estimated) US5366722 No 1994-11-22 2011-11-22 USRE36418 No 1999-11-30 2011-07-12
- Experimental Properties
Property Value Source logP 0.5 Not Available
- Predicted Properties
Property Value Source Water Solubility 0.185 mg/mL ALOGPS logP -2.9 ALOGPS logP -2.1 ChemAxon logS -3.9 ALOGPS pKa (Strongest Acidic) 11.43 ChemAxon pKa (Strongest Basic) -3.2 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 15 ChemAxon Hydrogen Donor Count 13 ChemAxon Polar Surface Area 339.09 Å2 ChemAxon Rotatable Bond Count 22 ChemAxon Refractivity 277.16 m3·mol-1 ChemAxon Polarizability 111.56 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon
- Predicted ADMET features
Property Value Probability Human Intestinal Absorption - 0.8058 Blood Brain Barrier - 0.6467 Caco-2 permeable - 0.6448 P-glycoprotein substrate Substrate 0.5344 P-glycoprotein inhibitor I Non-inhibitor 0.6189 P-glycoprotein inhibitor II Non-inhibitor 0.6578 Renal organic cation transporter Non-inhibitor 0.9372 CYP450 2C9 substrate Non-substrate 0.7589 CYP450 2D6 substrate Non-substrate 0.8157 CYP450 3A4 substrate Non-substrate 0.5826 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.907 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8309 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5808 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.6966 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 1.7030 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9948 hERG inhibition (predictor II) Non-inhibitor 0.521
- Mass Spec (NIST)
- Not Available
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
- This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.
- Organic compounds
- Super Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Acylaminobenzoic acid and derivatives
- Alternative Parents
- P-haloacetanilides / O-haloacetanilides / 2-halobenzoic acids and derivatives / 4-halobenzoic acids and derivatives / Benzamides / Benzoyl derivatives / Iodobenzenes / Aryl iodides / Vinylogous halides / Tertiary carboxylic acid amidesAcetamides / Secondary carboxylic acid amides / Secondary alcohols / Carbonyl compounds / Hydrocarbon derivatives / Organic oxides / Organoiodides / Organonitrogen compounds / Organopnictogen compounds / Primary alcohols show 10 more
- Acylaminobenzoic acid or derivatives / O-haloacetanilide / P-haloacetanilide / Haloacetanilide / Acetanilide / 2-halobenzoic acid or derivatives / 4-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Benzamide / AnilideBenzoyl / Iodobenzene / Halobenzene / Aryl iodide / Aryl halide / Vinylogous halide / Tertiary carboxylic acid amide / Acetamide / Carboxamide group / Secondary carboxylic acid amide / Secondary alcohol / Carboxylic acid derivative / Organoiodide / Organohalogen compound / Organic nitrogen compound / Alcohol / Carbonyl group / Hydrocarbon derivative / Organic oxide / Organopnictogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Primary alcohol / Aromatic homomonocyclic compound show 25 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- organoiodine compound (CHEBI:31705)
Drug created on March 30, 2007 01:03 / Updated on April 23, 2019 12:19